Rhyino, is this NEJM abstract what you are looking for?
KT
Paclitaxel–Carboplatin Alone or with
Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, M.D., Robert Gray, Ph.D., Michael C. Perry, M.D., Julie Brahmer, M.D.,
Joan H. Schiller, M.D., Afshin Dowlati, M.D., Rogerio Lilenbaum, M.D.,
and David H. Johnson, M.D.
From Vanderbilt University, Nashville (A.S.,
D.H.J.); the Dana–Farber Cancer Institute,
Boston (R.G.); the Ellis Fischel Cancer
Center, University of Missouri, Columbia
(M.C.P.); Johns Hopkins University, Baltimore
( J.B.); the University of Wisconsin,
Madison ( J.H.S.); University Hospitals of
Cleveland, Cleveland (A.D.); and Mount
Sinai Hospital, Miami (R.L.). Address reprint
requests to Dr. Sandler at the Vanderbilt–
Ingram Cancer Center, 2220 Pierce
Ave., Nashville, TN 37232, or at alan.
sandler@vanderbilt.edu.
N Engl J Med 2006;355:2542-50.
Copyright © 2006 Massachusetts Medical Society.
Abstract
Background
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor,
has been shown to benefit patients with a variety of cancers.
Methods
Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG)
conducted a randomized study in which 878 patients with recurrent or advanced
non–small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with
paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab
(434). Chemotherapy was administered every 3 weeks for six cycles, and
bevacizumab was administered every 3 weeks until disease progression was evident
or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases,
clinically significant hemoptysis, or inadequate organ function or performance
status (ECOG performance status, >1) were excluded. The primary end point
was overall survival.
Results
The median survival was 12.3 months in the group assigned to chemotherapy plus
bevacizumab, as compared with 10.3 months in the chemotherapy-alone group
(hazard ratio for death, 0.79; P = 0.003). The median progression-free survival in the
two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression,
0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).
Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001).
There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group,
including 5 from pulmonary hemorrhage.
Conclusions
The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of
selected patients with non–small-cell lung cancer has a significant survival benefit
with the risk of increased treatment-related deaths. (ClinicalTrials.gov number,
NCT00021060.)
AI
